Group 1 - The core viewpoint of the report indicates that the pattern of a "transformation bull market" in the Chinese stock market is becoming increasingly clear, with a strategic outlook favoring 2025 [1] - After adjustments, investors' understanding of the economic situation has become sufficient, reducing the marginal impact of valuation contraction [1] - Stock prices reflect investors' expectations for the future, with the main contradiction in expectation changes shifting from economic cycle fluctuations to a decline in discount rates, particularly the systematic reduction of risk-free rates and risk perception [1] Group 2 - The Chinese policy "three arrows" aimed at resolving debt, boosting demand, and stabilizing asset prices, along with capital market reforms focused on "investor-centric" approaches, are expected to help restore investor confidence in long-term assumptions [1] - The emergence of new technologies and new consumption opportunities is contributing to the revitalization of the investment landscape in China, supporting the transition towards a "transformation bull market" [1]

Group 1 - The transaction involves Shanghai Aopumai Biotechnology Co., Ltd. acquiring 100% equity of Pengli Bio-pharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment [1][2] - The industry classification of the target company falls under "M73 Scientific Research and Technical Services" specifically within "4.1 Biopharmaceutical Industry" [1][2] - The transaction is categorized as a vertical merger within the same industry, enhancing the company's CRDMO (Cell Culture Medium + Clinical CRO + Biopharmaceutical CDMO) service capabilities [2][3] Group 2 - The transaction includes issuing shares to no more than 35 specific investors to raise supporting funds [3] - The independent financial advisor confirms that the listed company is not under investigation by the China Securities Regulatory Commission (CSRC) [3]

Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., is planning to acquire 100% equity of Pengli Biological Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, involving multiple investment partners [1][2]. Group 1: Transaction Details - The acquisition involves several investment entities, including PharmaLegacy Hong Kong Limited and various limited partnerships, indicating a broad consortium of investors [1]. - The company intends to raise supporting funds by issuing shares to no more than 35 specific investors as part of the transaction [1]. Group 2: Confidentiality Measures - The company has implemented strict confidentiality measures to prevent the leakage of sensitive information related to the transaction, including the establishment of a registration system for insider information [2]. - The independent financial advisor has confirmed that the company has adhered to relevant laws and regulations, ensuring effective confidentiality protocols are in place [2].

Group 1 - The independent financial advisor, Guotai Junan Securities Co., Ltd., conducted a review of Shanghai Aopumai Biotechnology Co., Ltd.'s acquisition and financing activities, confirming compliance with the relevant regulations [1][2] - The review found no instances of direct or indirect paid hiring of third parties by the independent financial advisor during the financial advisory process for the merger and acquisition [1][2] - The hiring of third-party institutions and individuals by the listed company was deemed legal and compliant with the regulations set forth by the China Securities Regulatory Commission [2] Group 2 - The listed company did not engage in any other direct or indirect paid hiring of third-party institutions or individuals beyond those mentioned [2] - The independent financial advisor's review opinion aligns with the regulations regarding the hiring of third parties in investment banking activities [2]

Core Viewpoint - The transaction by Shanghai Aopumai Biotechnology Co., Ltd. to acquire 100% equity of Pengli Bio-pharmaceutical Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment does not constitute a major asset restructuring as per the relevant regulations [1][2][4]. Group 1: Transaction Details - The transaction involves the acquisition of 100% equity of Pengli Bio-pharmaceutical by issuing shares and cash to multiple investors [1][2]. - The company plans to raise supporting funds by issuing shares to no more than 35 specific investors [2]. Group 2: Regulatory Compliance - The independent financial advisor, Guotai Junan Securities Co., Ltd., conducted a review and confirmed that the transaction does not lead to a change in control of the company [4]. - The current controlling shareholder is Mr. Xiao Zhihua, and the actual controllers are Mr. Xiao and Mrs. He Yunfen, indicating stability in control post-transaction [4].

国泰海通证券股份有限公司 关于 中科院成都信息技术股份有限公司发行股份 及支付现金购买资产并募集配套资金 暨关联交易 之部分限售股份解除限售的核查意见 独立财务顾问 （中国（上海）自由贸易试验区商城路 618 号） 签署日期：二〇二五年六月 国泰海通证券股份有限公司（以下简称"国泰海通证券"、"本独立财务顾问"） 作为中科院成都信息技术股份有限公司（以下简称"中科信息"、"上市公司"或"公 司"）发行股份及支付现金购买资产并募集配套资金暨关联交易（以下简称"本次 交易"）的独立财务顾问，根据《证券发行上市保荐业务管理办法》 《上市公司重 大资产重组管理办法》 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》等相关法律法规的 规定，对本次交易部分限售股份解除限售情况进行了审慎核查，具体核查情况如 下： 一、公司本次解除限售股份情况 （一）本次解除限售股份的发行及上市情况 管理委员会（以下简称"中国证监会"）于 2021 年 9 月 23 日出具的《关于同意中 科院成都信息技术股份有限公司向成都中科唯实仪器有限责任公司等发行股份 购买资产并募集配套资 ...

国泰海通证券股份有限公司 关于苏州市味知香食品股份有限公司 关于差异化权益分派特殊除权除息的业务申请的核查意见 国泰海通证券股份有限公司（以下简称"保荐机构"、"国泰海通"）作为 苏州市味知香食品股份有限公司（以下简称"味知香"、"公司"）持续督导的 保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市 《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 规则》 《上海证券 交易所上市公司自律监管指南第 2 号——业务办理》等有关规定，就味知香差异 化权益分派特殊除权除息的业务申请事项进行了审慎核查，发表核查意见如下： 一、审议通过的差异化权益分派方案 公司将按照以下公式计算除权除息开盘参考价： 除权（息）参考价格=（前收盘价格-现金红利）÷（1+流通股份变动比例） 公司于 2025 年 4 月 25 日召开第三届董事会第六次会议审议通过了《关于公 司 2024 年度利润分配方案的议案》，公司 2024 年度拟以实施权益分派股权登记 日登记的总股本扣除公司回购专用证券账户股份为基数分配利润，公司拟向全体 股东（公司回购专用证券账户除外）每 10 股派送现金红利人民币 3.60 元（ ...

Summary of Key Points Core Viewpoint The report outlines the verification opinions of Guotai Junan Securities Co., Ltd. regarding Puyuan Precision Technology Co., Ltd.'s use of its own funds and letters of credit to pay for part of the fundraising projects, which will later be replaced with equivalent amounts from the raised funds. This process is deemed compliant with relevant regulations and beneficial for operational efficiency. Group 1: Fundraising Overview - The company successfully issued 30,327,389 shares at a price of RMB 60.88 per share, raising a total of RMB 184,633.14 million, with a net amount of RMB 166,612.72 million after deducting issuance costs [1][2] - In a simplified procedure, the company issued 5,300,676 shares at RMB 54.71 per share, raising RMB 289.99 million, with a net amount of RMB 286.79 million after costs [2] - The company plans to issue 2,166,377 shares at RMB 23.08 per share for asset acquisition, raising RMB 49.99 million, with a net amount of RMB 44.29 million after costs [2] Group 2: Investment Projects - The total investment for the initial public offering (IPO) projects is RMB 76,763.12 million, with RMB 75,000.00 million allocated from the raised funds for various projects, including high-end digital oscilloscopes and RF instruments [3][4] - The simplified issuance project has a total investment of RMB 32,489.63 million, with RMB 29,000.00 million planned from the raised funds for projects in Malaysia and Xi'an [4] - The asset acquisition project has a total investment of RMB 5,296.04 million, with RMB 5,000.00 million planned from the raised funds for the Beijing laboratory center and related fees [4] Group 3: Use of Own Funds and Replacement Process - The company uses its own funds and letters of credit for initial payments on fundraising projects due to operational efficiency and regulatory constraints on direct payments from raised funds [5] - A detailed process is established for replacing the amounts paid with raised funds within six months, ensuring compliance with regulations and proper documentation [5] - The board and supervisory committee have approved this approach, confirming it does not harm the company's or shareholders' interests and complies with relevant laws [6][7]

Summary of Key Points Core Viewpoint - The company intends to use part of the excess raised funds to permanently supplement its working capital, which is deemed beneficial for improving fund utilization efficiency and reducing financial costs [1][5][9]. Group 1: Fundraising Overview - The company successfully completed its initial public offering (IPO) on April 1, 2022, issuing 30,327,389 shares at a price of RMB 60.88 per share, raising a total of RMB 184,633.14 million [1][7]. - After deducting issuance costs of RMB 18,020.43 million, the net amount raised was RMB 166,612.72 million, with excess funds amounting to RMB 91,612.72 million [1][3][7]. Group 2: Fund Utilization Plan - The planned allocation of the raised funds includes various projects, with a total investment of RMB 76,763.12 million, of which RMB 5,000 million is designated for working capital [3][5]. - The company has previously used RMB 27,400 million of excess funds for working capital, representing 29.91% of the total excess funds [3][6]. Group 3: Approval and Compliance - The board of directors and the supervisory board have approved the use of RMB 27,400 million of excess funds for working capital, which will be submitted for shareholder approval [6][8]. - The company commits that the total amount used for working capital will not exceed 30% of the excess funds within any 12-month period, ensuring compliance with regulatory requirements [6][9].

国泰海通证券股份有限公司 关于上海索辰信息科技股份有限公司 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为上海 索辰信息科技股份有限公司（以下简称"索辰科技"或"公司"）首次公开发行 股票并在科创板上市的保荐人，根据《中华人民共和国公司法》《中华人民共和 国证券法》 《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市 规则》 （以下简称"《上市规则》" ）和《上海证券交易所上市公司自律监管指引第 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： 一、本次现场检查的基本情况 国泰海通证券股份有限公司 （二）保荐代表人 程韬、陈佳一 程韬、陈佳一 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交易、对外担保、重大对 外投资、公司经营状况以及承诺履行情况等方面进行了现场检查。 （六）现场检查手段 员及有关人员访谈； 二、对现场检查相关事项的意见 （一）保荐人 （三）现场检查时间 （四）现场检查人员 营性资金往来情况。 经核查，保荐人认为：公司具备 ...